Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially high blood pressure and heart failure.
Quantum Genomics is developing a new therapeutic approach based on Brain Aminopeptidase A inhibition (BAPAI) , which results from more than twenty years of academic research in the laboratories of the Collège de France, INSERM and CNRS.
The research conducted by the team of Professor Bernard-Pierre Roques (INSERM U1022 / CNRS Unit/ Université Paris Descartes) and the team of Dr. Catherine Llorens-Cortes (INSERM U1050 / Collège de France) characterized the role of the brain renin-angiotensin system (RAS) and more particularly that of aminopeptidase A (APA) in the control of certain cardiovascular functions including blood pressure.
33 Rue Marbeuf, 75008 Paris – France
Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.